All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

When assessed as oxygen consumption (VO~2~), cardiorespiratory fitness (CRF) may be measured either using a treadmill with conventional gas analysis equipment (TM-VO~2meas~) or predicted from equations based on treadmill speed, incline or treadmill time (TM-VO~2pred~)\[[@pone.0166608.ref001]\]. The prognostic importance of CRF has been extensively investigated in recent meta-analyses confirming the strong inverse relationships between CRF and all-cause mortality in healthy individuals \[[@pone.0166608.ref002]\] and in patients with either coronary artery disease (CAD) or congestive heart failure (CHF) \[[@pone.0166608.ref003]--[@pone.0166608.ref006]\]. The prospective studies included in these reviews involve large numbers of subjects and have shown that a 1 MET (equal to 3.5 mL O~2~ ·kg^-1^·min^-1^) increment increase in CRF is associated with an approximate 10--20% reduction in all cause and cardiovascular mortality \[[@pone.0166608.ref002],[@pone.0166608.ref007]\] with a similar effect being observed with CHF \[[@pone.0166608.ref006],[@pone.0166608.ref008]\].

Logistics of large studies necessitate prediction of peak VO~2~ (VO~2peak~) as measurement of VO~2~ is costly and time consuming. Equations have been determined for the various treadmill protocols based on the variables of treadmill speed, incline or the test time for a particular protocol, a common reference being ACSM publications \[[@pone.0166608.ref001]\]. However, many factors may contribute to the error of TM-VO~2pred~. They include 1) treadmill handrail support \[[@pone.0166608.ref009]--[@pone.0166608.ref013]\], 2) failure to use population specific equations \[[@pone.0166608.ref014]--[@pone.0166608.ref018]\], 3) inappropriate testing protocol \[[@pone.0166608.ref019]--[@pone.0166608.ref021]\], 4) delayed oxygen kinetics \[[@pone.0166608.ref022]--[@pone.0166608.ref024]\], 5) reproducibility of cardiopulmonary parameters \[[@pone.0166608.ref025],[@pone.0166608.ref026]\], 6) altered mechanical efficiency with treadmill walking \[[@pone.0166608.ref027]\] and 7) lack of treadmill calibration \[[@pone.0166608.ref028]\].

Cardiovascular pathology frequently screened for with treadmill testing includes both CAD and CHF. In using CRF as an outcome measure from a treadmill test, VO~2peak~ is commonly expressed as METs with 1 MET being the VO~2~ at rest with current convention stating that it is equal to 3.5 mL O~2~ ·kg^-1^·min^-1^ \[[@pone.0166608.ref029]\]. Kaplan-Meier curves have been used extensively to document the link between CRF and long-term morbidity/mortality \[[@pone.0166608.ref030],[@pone.0166608.ref031]\]. Although VO~2~ can be predicted from treadmill speed, incline or the test time for a particular protocol, currently the only way to ensure an accurate measurement of VO~2~ is direct measurement with gas analysis. Using only two simple measurements, rest HR and an activity HR (either sub-maximal or maximal), the recently published HR index (HRI = activity HR/rest HR), equation for predicting VO~2~ expressed as METs is associated with a high correlation between HRI and VO~2~, the equation being METs = 6 x HRI -5 \[[@pone.0166608.ref032]\]. The HRI equation was derived from group mean data from 60 studies in which an exercise test contained a resting HR (HR~rest~), and a VO~2~ measured at the activity HR (either submaximal or peak) and expressed in the form of mLO~2~ ·kg^-1^·min^-1^ or METs. The original data are shown as a regression plot in [Fig 1](#pone.0166608.g001){ref-type="fig"}. The utility of this equation is that it provides a simple independent surrogate method of estimating VO~2~ using only the rest and either the sub-maximal or maximal activity HR measurements. Though the HRI equation was developed from aggregate data, there has been no analysis to date that has established its predictive accuracy for assessment of VO~2~.

![Linear regression plot of HR index equation.\
An analysis from data (n = 220) derived from 60 studies with the HR index equation simplified to METs = 6 x HR index-- 5.](pone.0166608.g001){#pone.0166608.g001}

The objective of this study was to compare aggregate HRI-derived VO~2~ (HRI-VO~2~) data against VO~2peak~ from two different treadmill tests, either: 1) VO~2~ measured with conventional gas analysis equipment (TM-VO~2meas~) or 2) VO~2~ predicted from equations based on treadmill speed, incline or treadmill time (TM-VO~2pred~).

Methods {#sec006}
=======

Study selection {#sec007}
---------------

Treadmill studies involving assessment of VO~2peak~, reporting either TM-VO~2meas~ or TM-VO~2pred~, were identified through a systematic search conducted on at least a monthly basis from October 2011 till March 2013 using MEDLINE, Google Scholar and Web of Science. Search terms included (in various combinations) exercise testing, oxygen uptake, VO~2~, CRF, cardiovascular disease (CVD), CAD, CHF and physical activity. With publications having the prerequisite HR data extensive cross-referencing was undertaken to source other publications with eligible criteria \[[@pone.0166608.ref033]\].

Eligibility criteria for study inclusion are 1) \>100 patients enrolled, 2) documented VO~2peak~ (either measured or predicted) expressed as either mL O~2~ ·kg^-1^·min^-1^ or as METs, 3) measured maximal HR (HR~max~) associated with VO~2peak~, and 4) measured HR~rest~. Where large scale studies included cycle ergometry in conjunction with treadmill testing, the study was excluded. In publications likely to have used a similar subject cohort based on 1. participating authors, 2. study location, 3. time period when the study was performed and 4. characteristics of the study population e.g. healthy, suspected or known CAD the most recent publication was chosen. From the HR data, a predicted MET value (VO~2peak~) was derived using the HRI equation (METs = 6 x HR index-- 5, where HR index is HR~max~/HR~rest~).

At the time of closure of data acquisition in March 2013 a total of 40 studies (TM-VO~2meas~; n = 20 studies, TM-VO~2pred~; n = 20 studies) had been identified with all but one being published since 1991. MEDLINE searching identified 19 of the 40 studies (TM-VO~2meas~; n = 11 studies, TM-VO~2pred~; n = 8 studies) used in this analysis with the remaining 21 studies being sourced through Web of Science, Google Scholar and cross referencing. The TM-VO~2meas~ studies had a bias towards clinical outcomes related to CHF whereas the TM-VO~2pred~ studies were frequently associated with long-term outcome (survival) in screening for CVD. Though multiple search strategies were used to obtain studies meeting selection criteria it is acknowledged that even with rigorous attention to search detail, suitable studies may have been missed.

[Fig 2](#pone.0166608.g002){ref-type="fig"} details the study selection process at the completion of data acquisition in March 2013.

![Study selection process used for data acquisition.](pone.0166608.g002){#pone.0166608.g002}

Statistical analysis {#sec008}
--------------------

Categorical variables were expressed as numbers and percentages with continuous variables expressed as mean ± standard deviation. Student's paired t-test was used to compare HRI-VO~2~ against both TM-VO~2meas~ and TM-VO~2pred~. Results are expressed in two formats, namely 1) pooled data for each of TM-VO~2meas~ and TM-VO~2pred~ against HRI-VO~2~ expressed as group means and shown in the form of line of identity and Bland Altman plots \[[@pone.0166608.ref034]\] and 2) CRF data shown in tertiles for both TM-VO~2meas~ and TM-VO~2pred~ groups against HRI-VO~2~.

Results {#sec009}
=======

Studies used in the analyses {#sec010}
----------------------------

There were 11,477 subjects in the 20 TM-VO~2meas~ studies (range 110 to 4631, median 337) and, with each study mean VO~2meas~ value representing a data point, there was a total of 45 data points. There was a considerably larger number of subjects at 105,044 (range 772 to 22,275, median 3,736) in the 20 TM-VO~2pred~ studies and, with each study mean VO~2pred~ value representing a data point, there were 57 data points. Age and gender distribution was similar for the TM-VO~2meas~ (51.0 years and 64.9% males) and TM-VO~2pred~ groups (52.9 years and 71.0% males).

The principal details of the 40 treadmill studies used in the analysis are outlined in [Table 1](#pone.0166608.t001){ref-type="table"}. These include the test protocol, use of handrail support and the health status of participants. Of the 20 TM-VO~2meas~ studies, 14 (70%) involved subjects with CHF and all 14 used protocols other than the standard Bruce protocol \[[@pone.0166608.ref035]\]. The design of these alternate protocols reduced the stage increment of VO~2~ usually to 2 METs or less with certain ramp protocols having increments of less than 1 MET per minute. In only two of the TM-VO~2meas~ studies was hand rail support mentioned, being 'not permitted' in one study (Dressendorfer \[[@pone.0166608.ref036]\]) and 'discouraged' in the other (Oliveira \[[@pone.0166608.ref037]\]).

10.1371/journal.pone.0166608.t001

###### Description of studies, patient diagnosis, and test protocol in which oxygen uptake was either measured or predicted using a prediction equation (Pred EQ).

![](pone.0166608.t001){#pone.0166608.t001g}

  First Author            Year   n       Age (years)   Male%   Category               Test        Rail support   Pred EQ
  ----------------------- ------ ------- ------------- ------- ---------------------- ----------- -------------- ---------
  ***Measured VO~2~***                                                                                           
  Bard                    2006   355     51            72      CHF                    ramp        ns             
  Diller                  2006   727     33            52      ACHD                   MB          ns             
  Dressendorfer           1993   182     57            100     CAD                    MB          NP             
  Elmariah                2006   594     52            72      CHF                    ramp        ns             
  Harrington              1997   131     59            100     CHF, H                 MB          ns             
  Ingle                   2007   394     65            74      CHF                    MB          ns             
  Jorde                   2008   278     52            77      CHF                    Na          ns             
  Kohrt                   1991   110     64            50      H                      B,O         ns             
  Kubrychtova             2009   712     56            72      CHF                    O           ns             
  Lanier                  2012   320     52            75      CHF                    Na          ns             
  McDonough               1970   144     51            100     H                      B           ns             
  Nes                     2012   4631    48            49      H                      ramp        ns             
  Oliveira                2009   948     57            100     CPD, H                 ramp        DIS            
  Osada                   1998   154     52            75      CHF                    MB, MNa     ns             
  Peterson                2003   369     51            72      CHF                    O           ns             
  Robbins                 1999   487     52            71      CHF, H                 Na          ns             
  Schalcher               2003   146     52            88      CHF                    ramp        ns             
  Stolker                 2006   221     49            68      CHF                    O           ns             
  Williams                2001   219     56            76      CHF                    B, MB       ns             
  Witte                   2006   355     66            68      CHF, H                 MB          ns             
  ***Predicted VO~2~***                                                                                          
  Adabag                  2008   12555   46            100     CAD**°**               B           ns             EQ-S
  Aijaz                   2008   10897   54            75      CVD, CVD**°**          B           ns             ns
  Arruda-Olson            2002   5798    62            57      CAD, CAD^**?**^        B, MB, Na   ns             ns
  Carnethon               2003   4487    25            45      H                      MBa         ns             ns
  Cheng                   2003   2333    49            100     DM                     MBa         ns             EQ-S
  Elhendy                 2001   1618    55            35      CAD^**?**^             B, MB, Na   ns             ns
  Gulati                  2010   5437    52            0       CAD**°**               B           LS             EQ-R
  Kim                     2007   22275   51            59      CVD**°**               B, MB, O    NP             EQ-R
  Kokkinos                2009   4631    61            100     HT                     B, ramp     DIS            EQ-R
  Lai                     2004   5625    59            100     CVD**°**               ramp, O     ns             EQ-R
  Lauer                   1999   2953    58            64      CVD**°**, CVD^**?**^   B, MB       NP             EQ-R
  Lipinski                2005   1914    52            100     CAD, CHF, CAD**°**     ramp, O     ns             ns
  Mahenthiran             2005   1268    60            52      CAD, CAD**°**          B           ns             ns
  McAuley                 2007   6876    58            97      CAD, CAD**°**          ramp        DIS            EQ-R
  Mora                    2003   2985    47            0       CAD**°**               B           ns             EQ-R
  Morrow                  1993   2546    59            100     CAD°, CAD, CHF         ramp, O     ns             EQ-R
  Myers                   2002   6213    59            100     CAD, CAD**°**          ramp        DIS            EQ-R
  Negishi                 2013   914     56            56      DM                     B, MB       NP             EQ-R
  Peteiro                 2010   2947    62            61      CAD, CAD^**?**^        B, MB, Na   ns             ns
  Shaw                    2011   772     63            0       CAD^**?**^             B, MB       ns             ns

References are available in the supplementary digital content. **Category:** ACHD, adult congenital heart disease; CAD, coronary artery disease (CAD**°**, absent; CAD^**?**^, suspected); CHF, congestive heart failure; CPD, cardiopulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus; H, healthy; HT, hypertension. **Treadmill test:** B, Bruce protocol; Ba, Balke protocol; Na, Naughton protocol; ramp, ramp protocol; M, modified protocol; O, other protocol; **Rail support**: ns, not stated; NP, not permitted; DIS, discouraged; LS, light support; **Equation**: EQ-S, stated equation; EQ-R, referenced equation; ns, not stated.

Typically, subjects with known or suspected CVD or with significant cardiovascular risk factors were involved in the TM-VO~2pred~ studies ([Table 1](#pone.0166608.t001){ref-type="table"}). A Bruce protocol, either as the standard or a modified protocol, was used in 13 (65%) of the 20 TM-VO~2pred~ studies. With TM-VO~2pred~ studies, the use of handrail support was defined in seven studies (35%) and not stated in the remaining 13 studies. Descriptors of handrail support used for these seven studies were 'discouraged' in 3 studies, 'not permitted' in 3 studies and 'light hand rail support' in 1 study. Predictive treadmill equations in TM-VO~2pred~ studies were either given or referenced in only 12 (60%) of the 20 studies.

Characterization of study groups {#sec011}
--------------------------------

### A. Group means: oxygen consumption and heart rate {#sec012}

The mean TM-VO~2pred~ reported in the 20 studies was 8.12 METS; the mean TM-VO~2meas~ reported in the 20 studies was 6.51 METS, a difference of 1.61 Mets or 24.7% ([Table 2](#pone.0166608.t002){ref-type="table"}). The mean HR~rest~ with TM-VO~2pred~ was 75.6 beats∙min^-1^ and with TM-VO~2meas~ was 77.6 beats∙min^-1^; the mean HR~max~ for TM-VO~2pred~ 146.3 beats∙min^-1^ and TM-VO~2meas~ 147.1 beats∙min^-1^ ([Table 2](#pone.0166608.t002){ref-type="table"}). However, the absolute differences in group means for HR~rest~ and HR~max~ between TM-VO~2pred~ and TM-VO~2meas~ were small at 2.0 beats∙min^-1^ for HR~rest~ and only 0.8 beat∙min^-1^ for HR~max~ ([Table 2](#pone.0166608.t002){ref-type="table"}).

10.1371/journal.pone.0166608.t002

###### Heart rate and oxygen consumption data for TM-VO~2meas~ and TM-VO~2pred~.

Group mean (± 1SD) heart rate (HR) and oxygen consumption (VO~2~) data. HR~rest~, HR~peak~, HRI-VO~2~ and VO~2peak~ for TM-VO~2meas~ and TM-VO~2pred~.

![](pone.0166608.t002){#pone.0166608.t002g}

                         Studies   Data points   HR~rest~ beats∙min^-1^   HR~peak~ beats∙min^-1^   VO~2peak~ METs   HRI-VO~2~ METs
  ---------------------- --------- ------------- ------------------------ ------------------------ ---------------- ----------------
  **TM-VO**~**2pred**~   20        57            75.6 ± 5.3               146.3 ± 16.6             8.12 ± 1.85      6.71 ± 1.92
  **TM-VO**~**2meas**~   20        45            77.6 ± 7.7               147.1 ± 18.8             6.51 ± 2.25      6.54 ± 2.28

Alternatively if VO~2peak~ is determined by HRI-VO~2~ the difference between TM-VO~2pred~ and TM-VO~2meas~ is reduced to only 0.17 MET or 2.6% (TM-VO~2pred~ 6.71 METs, TM-VO~2meas~ 6.54 METs), a not unexpected result in view of the small differences in HR~rest~ and HR~max~ between these two groups ([Table 2](#pone.0166608.t002){ref-type="table"}).

### B. Comparison of measured VO~2~ and predicted VO~2~ versus VO~2~ predicted by HRI {#sec013}

When using the HRI to calculate VO~2peak~, there was no significant difference (0.4%, p = 0.84) in the pooled VO~2~ data with mean (± SD) MET values of 6.51(±2.25) for TM-VO~2meas~ and 6.54 (±2.28) for HRI-VO~2~ ([Fig 3A](#pone.0166608.g003){ref-type="fig"}). However, a highly significant difference (21.1%, p\<0.001) was seen between TM-VO~2pred~ and HRI-VO~2~ with respective values of 8.12 (±1.85) METs and 6.71 (±1.92) METs ([Fig 3A](#pone.0166608.g003){ref-type="fig"}).

![Comparison of pooled data from 20 studies for TM-VO~2meas~ and TM-VO~2pred~ against HRI-VO~2~.\
A. Comparison of group mean data for 20 TM-VO~2meas~ and TM-VO~2pred~ studies against HRI-VO2 (mean ± SE), B. Comparison of cardiorespiratory fitness tertiles from 20 studies for TM-VO~2meas~ against HRI-VO~2~ (mean ±SE). Percentage difference between TM-VO~2meas~ and HRI-VO~2~ shown within figure and C. Comparison of cardiorespiratory fitness tertiles from 20 studies for TM-VO~2pred~ against HRI-VO~2~ (mean ±SE). Percentage difference between TM-VO~2pred~ and HRI-VO~2~ shown within figure.](pone.0166608.g003){#pone.0166608.g003}

Even when expressed in tertiles based on HRI-VO~2~, there were no significant differences between TM-VO~2meas~ and HRI-VO~2~ by VO~2~ tertile; tertile 1, 2.4% (p = 0.42), tertile 2, -4.1% (p = 0.18) and tertile 3, 0.7% (p = 0.83) ([Fig 3B](#pone.0166608.g003){ref-type="fig"}). By comparison, each tertile for the TM-VO~2pred~ groups showed a significant difference from HRI-VO~2~; tertile 1, 31.2% (p\<0.001), tertile 2, 29.6% (p\<0.001) and tertile 3, 9.1% (p = 0.03) ([Fig 3C](#pone.0166608.g003){ref-type="fig"}).

The plot of TM-VO~2meas~ against HRI-VO~2~ shows a uniform distribution around the line of identity with the Bland Altman plot suggesting that there is no bias between these two separate methods of determining VO~2peak~ ([Fig 4A and 4B](#pone.0166608.g004){ref-type="fig"}). However, a similar line of identity plot for TM-VO~2pred~ against HRI-VO~2~ indicates a strong bias with the Bland Altman plot indicating a systematic error in support of over-prediction of TM-VO~2pred~ ([Fig 5A and 5B](#pone.0166608.g005){ref-type="fig"}).

![Line of identity and Bland Altman plot for TM-VO~2meas~.\
A. Line of identity for TM-VO~2meas~ and B. against Bland Altman plot for TM-VO~2meas~ against HRI-VO~2~.](pone.0166608.g004){#pone.0166608.g004}

![Line of identity and Bland Altman plot for TM-VO~2pred~.\
**A.** Line of identity for TM-VO~2pred~ and B. against Bland Altman plot for TM-VO~2pred~ against HRI-VO~2~.](pone.0166608.g005){#pone.0166608.g005}

Discussion {#sec014}
==========

It is crucial to have high quality CRF data for use in epidemiological studies as management strategies involving both pharmacological and lifestyle intervention rely on this accuracy. The utility of the HRI equation \[[@pone.0166608.ref032]\] as a surrogate measure of VO~2~ expressed in METs is confirmed in this study when assessed against VO~2peak~ for both TM-VO~2meas~ measured with conventional gas analysis equipment and for TM-VO~2pred~ predicted from equations based on treadmill speed, incline or treadmill time. A close agreement between HRI-VO~2~ and TM-VO~2meas~ was observed in the 20 TM-VO~2meas~ studies with only a 0.4% difference (p = 0.84) between group means. By comparison, a highly significant 21.1% (p\<0.001) over-prediction of VO~2peak~ was observed when comparing HRI-VO~2~ against TM-VO~2pred~ in the 20 TM-VO~2pred~ studies. The magnitude of the potential error using TM-VO~2pred~ challenges the current methods of treadmill prediction of CRF which appear to lead to overestimation of CRF and potentially to false prognostic classification.

If the magnitude of the disparity between HRI-VO~2~ and TM-VO~2pred~ as shown in this study is, for example, applied to the outcome data of CRF as expressed in METs in the meta-analysis by Kodama \[[@pone.0166608.ref002]\], there is a strong likelihood of a false classification based on the over-prediction of CRF. For example, in treadmill studies investigating the effect of handrail support, a practice that lengthens treadmill time, VO~2peak~ is over-predicted by 20% to 30% \[[@pone.0166608.ref009]--[@pone.0166608.ref013],[@pone.0166608.ref017]\] which would lead to a potentially false prognostic classification of CRF. To correct for the consistently observed over-prediction of VO~2peak~ of around 20% resulting from the use of handrail support, Foster has developed simple modifications of the ACSM equations for use when handrail support is observed during treadmill testing \[[@pone.0166608.ref017]\]. None of the 20 TM-VO~2pred~ studies used in this analysis referenced use of the Foster or similar equations to correct for observed handrail support. This prediction error could potentially apply to other published studies that express results in the form of survival tables and Kaplan-Meier curves. The measurement of CRF is not only limited to CVD. CRF also defines long-term risk in both healthy subjects and other common medical conditions, such as stroke \[[@pone.0166608.ref038]\], dementia \[[@pone.0166608.ref039]\] and diabetes mellitus \[[@pone.0166608.ref040]\]. In the TM-VO~2pred~ group of studies, the smallest difference (9.1%) between HRI-VO~2~ and TM-VO~2pred~ was observed in the highest CRF tertile. Presumably, the fittest subjects find less difficulty with treadmill walking and so have less need for handrail support. Conversely, the least fit, i.e., the lowest tertile, are most likely to utilize handrail support, even when instructed otherwise, and, in the present study, they demonstrated a 31.2% difference between HRI-VO~2~ and TM-VO~2pred~. Results from the HUNT 3 Fitness Study also noted the greatest overestimation of VO~2peak~ in the least fit subjects \[[@pone.0166608.ref018]\].

Collectively the 20 TM-VO~2pred~ studies used in this analysis involve a tenfold greater number of subjects when compared with the 20 TM-VO~2meas~ studies, whether considering the total number of subjects (105,044 TM-VO~2pred~ versus 11,477 TM-VO~2meas~) or the median number (3,736 TM-VO~2pred~ versus 337 TM-VO~2meas~). This observation indicates an inherent bias in using predicted VO~2~ studies for epidemiological purposes. In recognizing the need for high quality population CRF data, the Fitness Registry and the Importance of Exercise: A National Database (FRIEND) was established in 2014 \[[@pone.0166608.ref041]\]. A recent publication from this group has provided age-related reference standards of CRF from 7783 tests in which VO~2max~ was determined by gas analysis, the authors highlighting the shortcomings of using TM-VO~2pred~ largely because of over-prediction of VO~2max~ associated with hand rail support \[[@pone.0166608.ref042]\]. Their statement together with the observations in the present review suggest that, for the continued use of TM-VO~2pred~ data, a reappraisal of current methods used for prediction of VO~2peak~ warrants consideration.

One important question arising from this analysis is the value of using maximal HRI to predict VO~2peak~ from HR derived values (rest and peak) as opposed to treadmill parameters (speed, incline or treadmill time). When calculating maximal HRI, two independent predictors of future CVD risk, namely an estimated VO~2peak~ \[[@pone.0166608.ref002],[@pone.0166608.ref043]\] and HR~rest~ \[[@pone.0166608.ref044]\] are incorporated within the HRI. The maximal HRI is based on two measured values of HR and, when used as an index, there is minimal predictive error especially when compared to VO~2pred~ using equations based on speed, incline or treadmill time. As a 1.0 MET increment corresponds to a HRI increment of 0.167, Kaplan-Meier curves ranging from \<5 to \>10 METs have a corresponding HRI range from \<1.67 to \>2.50 (e.g., 5 METs = Rest \[HRI = 1\] + 4 METs \[HRI = 4 x 0.167\] = 1.67). In considering a range of activity from rest (1.0 MET) to the maximum aerobic performance of an elite athlete (e.g. 19 METs), the corresponding range of HRI would be from 1 to 4. The simplicity of calculating HRI together with the range of index used for clinical evaluation suggests that it could provide a useful addition to the assessment of CRF. To illustrate this, a range of 5, 10 and 15 MET levels have corresponding HRIs of 1.67, 2.5 and 3.33.

Study Limitations {#sec015}
=================

This review has used the simple concept of HRI as a surrogate measure of VO~2~. The equation was established from aggregate data acquired from 60 studies. In applying the HR index to this analysis, we have compared aggregate data from TM-VO~2pred~ and TM-VO~2meas~ against HRI-VO~2~ with no intention of indicating the individual predictive accuracy of the equation. Ideally the use of individual, as opposed to aggregate data would have been preferable but it was beyond the capability of this analysis.

Conclusions {#sec016}
===========

The usefulness of CRF is well established for assessing CV risk with treadmill testing providing a simple and convenient method of assessing CRF. The aggregate analysis used in this study shows a close relationship, i.e., a non-significant 0.4% difference, between HRI-VO~2~ and TM-VO~2meas~ but a large and highly significant 21.1% difference between HRI-VO~2~ and TM-VO~2pred~.This overestimation of TM-VO~2pred~, and so CRF, challenges the validity of predicting VO~2\ peak~ from equations based on treadmill speed, incline or protocol time when attempting to document a link between CRF and long-term morbidity/mortality.

Supporting Information {#sec017}
======================

###### Supplementary Reference List-- 40 treadmill studies.

File listing the 40 treadmill studies used for analysis.
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Click here for additional data file.
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